dyskinesia

(redirected from Dyskinesias)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to dyskinesia

abnormality in performing voluntary muscle movements

References in periodicals archive ?
Additionally, most patients also may experience dyskinesias, involuntary movements associated with most treatments used to manage the disease.
However, more dyskinesia and motor fluctuations are the trade-offs.
The aim of the study is primarily to determine the safety and tolerability of ACR325 and secondly to assess the effects of the compound on dyskinesias.
Although dyskinesias are very common, in the majority of patients they do not have a major impact on quality of life and may be improved by adjusting medication.
Effectiveness of ivermectin in rats with haloperidol induced tardive dyskinesia
Targeted symptoms included the following: dyskinesias (n=13), motor symptomatology (n=15), wearing off (n=2), and freezing (n=3).
While levodopa treatment is the gold standard in terms of potency and effectiveness, it leads to response fluctuations and dyskinesias, portrayed as abnormal movements usually seen at peak dose (Clarke & Guttman, 2002).
Dyskinesias may occur following peaks of L-dopa concentration and subside as the concentration declines but may also occur after low L-dopa concentration.
today reported positive results from a clinical study of eltoprazine in levodopa induced dyskinesia (LID) in Parkinson's disease (PD) patients.
announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston.
Dyskinesias increase with emotional arousal, activation, or distraction, and diminish with relaxation, sleep, or volitional effort.
I started him on an acetylcholinesterase inhibitor, which controlled the tardive dystonia and left the patient free of dyskinesias.
We believe that, by maintaining a steady levodopa blood concentration, ND0601 should minimize or even abolish dyskinesias and other disabling motor complications associated with long-term oral levodopa administration in advanced Parkinson's disease.
Continuous dopamine delivery systems have generated a great deal of interest because it is hypothesized that dyskinesias -- disruptive, jerky movements associated with long-term levodopa therapy -- result from the sharp fluctuations in dopamine blood levels that occur when levodopa is given orally.